Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      MicroRNAs*/blood ; COVID-19*/diagnosis ; COVID-19*/blood ; COVID-19*/virology ; Angiotensin-Converting Enzyme 2*/blood ; Angiotensin-Converting Enzyme 2*/genetics ; Angiotensin II*/blood ; SARS-CoV-2*; Humans ; Male ; Female ; Case-Control Studies ; Middle Aged ; Adult ; Biomarkers/blood ; Aged
    • Abstract:
      Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious virus that uses angiotensin converting enzyme 2 (ACE2), a pivotal member of the renin-angiotensin system (RAS), as its cell-entry receptor. Another member of the RAS, angiotensin II (Ang II), is the major biologically active component in this system. There is growing evidence suggesting that serum miRNAs could serve as prognostic biomarkers for SARS-CoV-2 infection and regulate ACE2 expression. Therefore, the aim of this study is to evaluate the changes in the serum levels of sACE2 and Ang II, as well as the expression level of miR-141-3p and miR-421 in SARS-CoV-2 positive and negative subjects.
      Methods: In the present study, the serum levels of sACE2 and Ang II were measured in 94 SARS-CoV-2 positive patients and 94 SARS-CoV-2 negative subjects with some symptoms similar to those of SARS-CoV-2 positive patients using the ELISA method. In addition, the expression level of miR-141-3p and miR-421 as ACE2 regulators and biomarkers was evaluated using quantitative real-time PCR (qRT-PCR) method.
      Results: The mean serum sACE2 concentration in the SARS-CoV-2-positive group was 3.268 ± 0.410 ng/ml, whereas in the SARS-CoV-2 negative group, it was 3.564 ± 0.437 ng/ml. Additionally, the mean serum Ang II level in the SARS-CoV-2 positive and negative groups were 60.67 ± 6.192 ng/L and 67.97 ± 6.837 ng/L, respectively. However, there was no significant difference in the serum levels of sACE2 (P value: 0.516) and Ang II (P value: 0.134) between the SARS-CoV-2 positive and negative groups. Meanwhile, our findings indicated that the expression levels of miR-141-3p and miR-421 in SARS-CoV-2 positive group were significantly lower and higher than SARS-CoV-2 negative group, respectively (P value < 0.001).
      Conclusions: Taken together, the results of this study showed that the serum levels of sACE2 and Ang II in SARS-CoV-2 positive and negative subjects were not significantly different, but the expression levels of miR-141-3p and miR-421 were altered in SARS-CoV-2 positive patients which need more investigation to be used as biomarkers for COVID-19 diagnosis.
      (© 2024. The Author(s).)
    • References:
      Turk J Med Sci. 2020 Apr 15;50(SI-1):571-577. (PMID: 32293835)
      Front Immunol. 2022 Mar 23;13:836516. (PMID: 35401548)
      Endocr Metab Immune Disord Drug Targets. 2023;23(1):70-76. (PMID: 35747972)
      Diagnostics (Basel). 2022 Apr 01;12(4):. (PMID: 35453934)
      J Clin Med. 2022 Nov 17;11(22):. (PMID: 36431276)
      Front Med (Lausanne). 2022 Dec 08;9:1058120. (PMID: 36569121)
      Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
      Iran J Allergy Asthma Immunol. 2022 Jun 18;21(3):254-262. (PMID: 35822676)
      Biotechnol Appl Biochem. 2022 Feb;69(1):124-128. (PMID: 33347649)
      Health Sci Rep. 2021 Nov 17;4(4):e440. (PMID: 34869917)
      J Pathol. 2020 Jul;251(3):228-248. (PMID: 32418199)
      ERJ Open Res. 2021 Mar 15;7(1):. (PMID: 33738305)
      Front Immunol. 2021 Jan 14;11:577875. (PMID: 33519802)
      Clin Infect Dis. 2021 Jun 15;72(12):e1004-e1009. (PMID: 33252659)
      Sci Rep. 2022 Nov 22;12(1):20117. (PMID: 36418458)
      Am J Hypertens. 2021 Apr 2;34(3):278-281. (PMID: 33043967)
      Biomark Insights. 2022 Sep 21;17:11772719221125123. (PMID: 36156891)
      Cell Host Microbe. 2016 Feb 10;19(2):181-93. (PMID: 26867177)
      Life (Basel). 2022 Apr 12;12(4):. (PMID: 35455065)
      Pharmacol Rep. 2021 Dec;73(6):1539-1550. (PMID: 34176080)
      Clin Sci (Lond). 2014 Aug;127(4):243-9. (PMID: 24564768)
      Diagnostics (Basel). 2023 Mar 14;13(6):. (PMID: 36980399)
      Lancet. 2020 Oct 3;396(10256):968-976. (PMID: 33010842)
      PLoS One. 2020 Jul 29;15(7):e0235987. (PMID: 32726325)
      J Med Virol. 2021 Oct;93(10):5908-5916. (PMID: 34138483)
      Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6. (PMID: 19321428)
      Int J Mol Sci. 2023 Sep 11;24(18):. (PMID: 37762258)
      J Biol Chem. 2005 Nov 25;280(47):39353-62. (PMID: 16166094)
      Respir Med. 2020 Jul;168:105996. (PMID: 32364961)
      Hypertension. 2020 Nov;76(5):e34-e36. (PMID: 32851897)
      Crit Care. 2017 Dec 28;21(1):329. (PMID: 29284527)
      Int J Antimicrob Agents. 2020 Jun;55(6):106006. (PMID: 32371096)
      Cells. 2021 Jul 13;10(7):. (PMID: 34359936)
      Crit Rev Eukaryot Gene Expr. 2019;29(4):333-342. (PMID: 31679294)
      Int J Infect Dis. 2020 Dec;101:42-45. (PMID: 32950735)
      Mol Syst Biol. 2021 Apr;17(4):e10232. (PMID: 33904651)
      Nat Commun. 2014 May 06;5:3595. (PMID: 24800963)
      Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919. (PMID: 33389262)
      Front Immunol. 2022 Aug 11;13:968991. (PMID: 36032130)
      Front Cell Infect Microbiol. 2022 Jan 14;11:789180. (PMID: 35096642)
      Int J Infect Dis. 2021 Feb;103:412-414. (PMID: 33249290)
      Drug Discov Today Dis Mech. 2006 Summer;3(2):225-229. (PMID: 32288774)
      Front Cell Infect Microbiol. 2020 Jun 05;10:317. (PMID: 32582574)
      Sci Rep. 2022 Mar 8;12(1):4058. (PMID: 35260724)
      Science. 2022 Mar 11;375(6585):1122-1127. (PMID: 35271343)
      PLoS One. 2021 Jun 4;16(6):e0252799. (PMID: 34086837)
      Nat Hum Behav. 2020 Dec;4(12):1303-1312. (PMID: 33199859)
    • Contributed Indexing:
      Keywords: Angiotensin II; Angiotensin converting enzyme 2; COVID-19; SARS-CoV-2; miR-141-3p; miR-421
    • Accession Number:
      0 (MicroRNAs)
      EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
      11128-99-7 (Angiotensin II)
      0 (MIRN141 microRNA, human)
      EC 3.4.17.23 (ACE2 protein, human)
      0 (MIRN421 microRNA, human)
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20240422 Date Completed: 20240429 Latest Revision: 20240503
    • Publication Date:
      20240504
    • Accession Number:
      PMC11036566
    • Accession Number:
      10.1186/s12879-024-09310-3
    • Accession Number:
      38649818